LOVFF (Cannara Biotech) Current Deferred Taxes Liabilities: $0.00 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LOVFF Cannara Biotech Inc LOVFF
88 GF Score
Price $1.46
GF Value $1.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cannara Biotech Current Deferred Taxes Liabilities?

Cannara Biotech LOVFF +2.03% 88 Current Deferred Taxes Liabilities is $0.00 Mil as of May. 2026. GuruFocus rates LOVFF with a GF Score™ of 88/100 and a GF Value™ of $1.22 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Cannara Biotech's current deferred tax liabilities for the quarter that ended in May. 2026 was $0.00 Mil.

Cannara Biotech Current Deferred Taxes Liabilities Related Terms

Cannara Biotech Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Current Deferred Taxes Liabilities Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cannara Biotech Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LOVFF
88GF Score
Cannara Biotech Inc LOVFF
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Cannara Biotech (LOVFF) has a Current Deferred Taxes Liabilities of $0.00 Mil as of May. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Current Deferred Taxes Liabilities too high?
Cannara Biotech's current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Cannara Biotech has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Current Deferred Taxes Liabilities compare to ZTS?
Cannara Biotech's Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Drug Manufacturers company?
A good Current Deferred Taxes Liabilities depends on the Drug Manufacturers industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.22, compared to a current price of $1.46 — trading 19.7% above its estimated fair value. The current Current Deferred Taxes Liabilities is $0.00 Mil. Cannara Biotech's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Current Deferred Taxes Liabilities is $0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.46 is trading 19.7% above its estimated GF Value™ of $1.22. GuruFocus considers Cannara Biotech to be Modestly Overvalued.

Key valuation signals for LOVFF:

  • Current Deferred Taxes Liabilities: $0.00 Mil
  • GF Value™: $1.22 vs. price of $1.46 (19.7% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
88GF Score

Get the complete analysis for LOVFF

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$1.22
GF Value